Greenleaf Trust Has $1.78 Million Stake in AstraZeneca PLC (NASDAQ:AZN)

Greenleaf Trust increased its holdings in AstraZeneca PLC (NASDAQ:AZN) by 4.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 27,104 shares of the company’s stock after buying an additional 1,210 shares during the period. Greenleaf Trust’s holdings in AstraZeneca were worth $1,776,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors also recently made changes to their positions in AZN. FMR LLC increased its stake in AstraZeneca by 1.1% in the third quarter. FMR LLC now owns 23,117,447 shares of the company’s stock valued at $1,801,080,000 after acquiring an additional 258,477 shares during the last quarter. Franklin Resources Inc. increased its stake in AstraZeneca by 8.7% in the third quarter. Franklin Resources Inc. now owns 19,122,675 shares of the company’s stock valued at $1,492,649,000 after acquiring an additional 1,522,715 shares during the last quarter. Fisher Asset Management LLC increased its stake in AstraZeneca by 5.3% in the third quarter. Fisher Asset Management LLC now owns 10,480,160 shares of the company’s stock valued at $816,509,000 after acquiring an additional 524,175 shares during the last quarter. Manning & Napier Advisors LLC grew its stake in shares of AstraZeneca by 17.7% during the fourth quarter. Manning & Napier Advisors LLC now owns 3,745,531 shares of the company’s stock worth $245,407,000 after buying an additional 564,297 shares during the last quarter. Finally, Bank of Montreal Can grew its stake in shares of AstraZeneca by 109.6% during the third quarter. Bank of Montreal Can now owns 3,071,333 shares of the company’s stock worth $238,397,000 after buying an additional 1,605,758 shares during the last quarter. 20.35% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on AZN. Deutsche Bank Aktiengesellschaft raised shares of AstraZeneca from a “sell” rating to a “hold” rating in a research note on Wednesday, November 6th. UBS Group raised shares of AstraZeneca from a “sell” rating to a “neutral” rating in a research note on Wednesday, November 20th. Two research analysts have rated the stock with a hold rating, five have assigned a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, AstraZeneca has an average rating of “Buy” and a consensus target price of $89.75.

AstraZeneca Price Performance

Shares of NASDAQ:AZN opened at $70.76 on Monday. The firm has a market cap of $219.43 billion, a PE ratio of 33.86, a price-to-earnings-growth ratio of 1.18 and a beta of 0.46. The firm’s fifty day moving average is $67.08 and its 200-day moving average is $73.89. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.71 and a current ratio of 0.93. AstraZeneca PLC has a 52 week low of $60.47 and a 52 week high of $87.68.

AstraZeneca (NASDAQ:AZN) last issued its quarterly earnings results on Tuesday, November 12th. The company reported $1.04 EPS for the quarter, topping analysts’ consensus estimates of $1.01 by $0.03. The company had revenue of $13.57 billion for the quarter, compared to analyst estimates of $13.08 billion. AstraZeneca had a net margin of 12.68% and a return on equity of 30.01%. AstraZeneca’s revenue was up 18.0% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.87 earnings per share. Sell-side analysts predict that AstraZeneca PLC will post 4.13 earnings per share for the current year.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.